ClinicalTrials.gg
CompletedNCT05253417CANRESTUpdated Aug 16, 2023

The CANabidiol Use for RElief of Short Term Insomnia

A Phase 2 interventional study of 50 mg Cannabidiol (CBD) and Placebo in Sleep Disturbance, Insomnia and Insomnia Type; Sleep Disorder, sponsored by Bod Australia. Completed at 2 sites in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-16.

Sponsored by Bod Australia · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia — 9 open to participants now, 10 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Australia.

Enrollment
14th of 25
208 · median 270
Started
2022
with 2 others
Phase 2
4 of 25
2 open now
Registered
12th of 25
by date
Lead sponsor
1 of 25
Bod Australia

Among the 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia, this one is the 14th largest by enrollment, is one of 3 that started in 2022, is one of 4 in phase 2, and was the 12th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

9 of the 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia, or all of them as a file.
02

Study summary

This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.

Read the detailed description

This is a double-blind, randomised, parallel-group, placebo-controlled study of 8 weeks of oral CBD at 50 or 100 mg per day versus placebo in 198 participants with insomnia symptoms as classified by an Insomnia Severity Index (ISI) score of 8-21. Participants will be recruited voluntarily and are able to withdraw at any time. The study will be conducted online with telehealth consults where required.

03

Conditions studied

  • Sleep Disturbance
  • Insomnia
  • Insomnia Type; Sleep Disorder
  • Insomnia, Transient
  • Insomnia Due to Anxiety and Fear
  • Insomnia Due to Other Mental Disorder

Keywords

  • Insomnia
  • sleep
  • fatigue
  • cannabidiol
  • CBD
  • mental health
  • anxiety
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and females aged 18-65 years old, inclusive.
  2. Females must be non-pregnant, non-lactating.
  3. Proficient in English and have internet access and a mobile phone.
  4. Insomnia symptoms as classified by an Insomnia Severity Index (ISI) score of 8 - 21 and have experienced these symptoms over the past month at pre-screening.
  5. Stated willingness to comply with all study procedures and availability for the duration of the study.
  6. Provision of signed and dated form.
  7. All male and females of must agree to use two forms of effective from the time of signing informed consent until 30 days after study completion.

Exclusion criteria

Exclusion Criteria:

  1. Serious medical and/or psychiatric illnesses/disorders that will require treatment during the trial period.
  2. The use of any drug known to affect sleep during the study one week prior the randomization, including:

    1. Sedatives (benzodiazepines, Z drugs, agomelatine, suvorexant, sodium oxybate, sedating antidepressants, sedating antihistamines, antipsychotics, melatonin, valerian).
    2. Opioids (e.g. morphine, codeine, oxycodone, methadone, buprenorphine, fentanyl, tramadol, tapentadol, hydromorphone).
    3. Stimulants (e.g. methylphenidate, dexamphetamine, modafinil, phentermine).
  3. Excessive caffeine use (defined as > 600mg caffeine or approximately 6 cups of caffeinated beverages a day) that, in the opinion of the medical doctor, contributes to the participant's insomnia.
  4. Excessive alcohol use (defined as per NHMRC guideline, i.e. no more than four standard drinks per day on average for men, and for women, no more than two).
  5. The use of cannabinoids or a cannabinoid-based medicine within 3 months prior to study Day 1 and unwillingness to abstain from recreational drug use during the study period.
  6. Cannabis dependence or any other drug or alcohol dependence within the past two years.
  7. Positive urine drug screen (e.g., amphetamines type substances, benzodiazepines, cannabinoids, cocaine, and opiates) at screening or Day -1 or a history of drug abuse within the past 2 years.
  8. Known to cannabis-based products or any of the in the study drug.
  9. Use of any drug or involvement in another clinical trial within 30 days of screening day.
  10. Use of anti-coagulant drugs such as warfarin or those known to be metabolised by CYP450 enzymes.
  11. Current or ongoing treatments for insomnia (e.g. cognitive-behavioural therapy (CBT) and CNS-active drugs).
  12. Obstructive sleep apnoea determined by the MAPI questionnaire or other self-reported sleep disorders.
  13. Medical conditions that result in frequent sleep disturbance (e.g. nocturia).
  14. History of attempted suicide in the past 12 months.
  15. hepatic abnormalities determined by the screening blood test.
  16. Shift work, jet lag or trans-meridian travel (two time zones) in the past month.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    50 mg CBD

    50 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Two capsules to be taken (plus two placebo capsules)

    Drug: 50 mg Cannabidiol (CBD) · Drug: Placebo · Drug: 100 mg Cannabidiol (CBD)

  • Experimental
    100 mg CBD

    100 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Four capsules to be taken.

    Drug: 50 mg Cannabidiol (CBD) · Drug: 100 mg Cannabidiol (CBD)

  • Placebo comparator
    Placebo

    Placebo capsules contain no CBD. Four capsules to be taken as a single oral dose.

    Drug: Placebo

Interventions

  • For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.

    Also known as: BodECS BioAbsorb(TM) capsule

  • DrugPlacebo

    Participants take four (4) placebo capsules.

  • For the study arm, '100 mg CBD' participants take four (4) CBD capsules.

    Also known as: BodECS BioAbsorb(TM) capsule

06

What researchers measure

Primary outcomes

  1. To investigate the effect of the administration of a 50mg and 100mg per day oral CBD product versus placebo over 8 weeks on insomnia severity index scores

    Insomnia Severity Index (ISI): A 7-item tool measuring the nature, severity, and impact of insomnia over the past 2 weeks. Each item uses a 5-point Likert scale to capture a rating (0 = no problem; 4 = very severe problem) which add up to: no insomnia (0 - 7); sub-threshold insomnia (8 - 14); moderate insomnia (15 - 21); and severe insomnia (22 - 28).

    Time frame: Baseline (week 0), week 4, week 8

Secondary outcomes

  1. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on wake after sleep onset (WASO) as assessed by actigraphy.

    WASO is a parameter that examines the total amount of minutes awake after the first sleep epoch is achieved. Therefore, as the WASO increases, sleep efficiency decreases.

    Time frame: Baseline (week 0), week 8

  2. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Anxiety as assessed by the DASS-21 questionnaire.

    Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).

    Time frame: Baseline (week 0), Week 4, week 8

  3. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Stress as assessed by the DASS-21 questionnaire.

    Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).

    Time frame: Baseline (week 0), Week 4, week 8

Other outcomes

  1. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Sleep onset latency (SOL) measured by actigraphy.

    Sleep onset latency (SOL) is the time it takes to transition from wakefulness to non-REM sleep. On average, the SOL should take between 10-20 minutes. Short sleep latencies usually reflect increased sleepiness.

    Time frame: Baseline (week 0), week 8

  2. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on subjective sleep as assessed by sleep diaries

    Participants will be requested to complete a short, 5-minute online sleep diary for seven mornings to describe the previous night's sleep at baseline, week 4 and week 8.

    Time frame: Baseline (week 0), week 4, week 8

  3. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on self-perception of improvement in sleep as assessed by a self-report questionnaire.

    The self-report questionnaire will ask participants to rate their self-perceived improvement in sleep using a standard 10-point visual analogue scale at weeks 4 and 8

    Time frame: Baseline (week 0), week 4, week 8

  4. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Subjective sleep-related quality of life as assessed by the Functional Outcomes Sleep Questionnaire (FOSQ-10).

    FOSQ-10 is a 10 items questionnaire to measure the impact of daytime sleepiness on activities of daily living. The score range is 5-20 points, with higher scores indicating better functional status.

    Time frame: Baseline (week 0), week 4, week 8

  5. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Fatigue assessed by the Flinders Fatigue Scale;

    The Flinders Fatigue Scale is a 7 items self-report scale which assess fatigue over the past 2 weeks. This scale provides a total fatigue score ranging from 0 to 31, with higher scores indicating greater fatigue.

    Time frame: Baseline (week 0), week 4, week 8

  6. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Health-related quality of life (HRQoL) assessed using the EQ-5D-5L.

    A descriptive system for health-related quality of life states in adults, consisting of five dimensions. Each of which has five severity levels that are described by statements appropriate to that dimension. Those are rated by a verbal 5-point rating scale allowing for distinction of five levels ('5L') of severity: Level 1: no problems; Level 2: slight problems; Level 3: moderate problems; Level 4: severe problems; Level 5: extreme problems per dimension and providing a 1-digit number for each dimension.

    Time frame: Baseline (week 0), week 4, week 8

  7. To determine the effect of 8 weeks of 50mg or 100mg of CBD on the number of participants with treatment-emergent adverse events

    The safety and tolerability of the investigational product will be determined by evaluating all incidences of treatment-emergent adverse events as assessed by reported by participants or observed by the investigators or from the safety pathology tests.

    Time frame: Week 4, Week 8, Week 12

  8. To determine relationship between efficacy endpoint and systemic concentrations of CBD and its carboxy and hydroxy metabolites

    Systemic concentrations of CBD (ng/mL), 7- hydroxycannabidiol (7-OH-CBD) (ng/mL) and 7- carboxycannabidiol (7- COOH-CBD) (ng/mL) will be analysed in plasma and urine samples collected at baseline and week 8.

    Time frame: Baseline (week 0), week 8

  9. To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Depression as assessed by the DASS-21 questionnaire.

    Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).

    Time frame: Baseline (week 0), Week 4, week 8

07

Study locations

2 sites
  • Woolcock Institute
    Glebe, New South Wales 2037, Australia
  • Fusion Clinical Research
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2023, 14 months.

Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 14 months is close to that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Feb 23, 2022
StartActual
May 1, 2022
Primary completionActual
Jul 7, 2023
CompletionActual
Jul 7, 2023
Last update
Aug 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05253417
Lead sponsor
Bod Australia
Collaborators
Woolcock Institute of Medical Research
Responsible party
Sponsor
First posted
Feb 23, 2022
Start date
May 1, 2022
Primary completion
Jul 7, 2023
Completion
Jul 7, 2023
Last update
Aug 16, 2023

Study contacts

Ron Grunstein
principal investigator · Woolcock Institute of Medical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion